Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Chief Legal Officer | May 13, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 400,703 |
Ending reported balance
After 2026-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-13 · Exercise / conversion · Acquired 62,500 · Balance 463,203 F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Row 2 · 2026-05-13 · Sale · Disposed 62,500 · Balance 400,703 F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2027-12-20 | Direct | 0 |
Reported balance
After 2026-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-13 · Exercise / conversion · Disposed 62,500 · Balance 0 F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F2: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
F2: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2020 Filed Feb 19, 2020 22:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 21,700 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-006505 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,700 Underlying: Common Stock · 21,700 shares Expires 2024-12-22 F1 · date: On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:55 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035553 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 20,000 | $1.45 | $29,000.00 |
DisclosureSEC source: 0001127602-19-033008 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,061 Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:38 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 423 | $8.07 | $3,413.61 |
DisclosureSEC source: 0001127602-19-000736 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,530 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:15 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0001127602-18-037182 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2028-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-18-035081 · form4.xml · derivative · entry 3 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 44,290 | $9.07 | $401,710.30 |
DisclosureSEC source: 0001127602-18-035081 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,953 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $9.00 to $9.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 25,000 | $1.42 | $35,500.00 |
DisclosureSEC source: 0001127602-18-035081 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 17, 2018 13:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-18-017800 · form4.xml · derivative · entry 3 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,132 Underlying: Common Stock · 12,500 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 17, 2018 13:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 3,004 | $5.91 | $17,753.64 |
DisclosureSEC source: 0001127602-18-017800 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,264 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise. Read SEC document |
| May 15, 2018 Filed May 17, 2018 13:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 12,500 | $1.42 | $17,750.00 |
DisclosureSEC source: 0001127602-18-017800 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 6,709 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001127602-18-009566 · form4.xml · derivative · entry 2 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,709 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 6,709 | $3.26 | $21,871.34 |
DisclosureSEC source: 0001127602-18-009566 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2018 Filed Jan 23, 2018 14:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 1,961 | $5.59 | $10,961.99 |
DisclosureSEC source: 0001127602-18-002237 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,129 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 14:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 459 | $4.91 | $2,253.69 |
DisclosureSEC source: 0001127602-18-000308 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,090 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 15:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-17-035406 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2027-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 18,600 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-17-026942 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2024-12-22 F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:53 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001127602-17-009101 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-02-27 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 14:28 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 2,599 | $5.95 | $15,464.05 |
DisclosureSEC source: 0001127602-17-002252 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,497 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 19:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 1,281 | $6.33 | $8,108.73 |
DisclosureSEC source: 0001127602-17-000087 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,096 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013 and 2015. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 14:54 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 8,357 | $4.27 | $35,684.39 |
DisclosureSEC source: 0001127602-16-062585 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,377 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 17, 2016. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.22 to $4.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.